Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mylan’s EpiPen Recall: Adding Insult To An Injured Product

Apr 04 2017

• By Sue Sutter

EpiPen

Related Content

Establishment Fees Protect American Manufacturing, Mylan Argues In User Fee Proposal

Dec 20 2010

Mylan Hit With GMP Warning Letter Despite Quality Improvement Efforts

Aug 18 2015

GDUFA Implementation Will Be Overseen By Mylan’s Representative in the House

Dec 04 2012

Mylan’s Generic Advair Delay Gives Leverage To Rivals

Mar 30 2017

Mylan Gets First-Ever GMP Warning Letter

Nov 22 2011

Diabetes Rebate Model Challenged On Morality Grounds In Class Action Suit

Jan 31 2017

EpiPen Rival Heads Back To Market After kaléo Retools With ‘100% Automated’ Production

Jan 20 2017

EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review

Aug 30 2016

Fast Like EpiPen: Mylan Reaches Quick Settlement Over Medicaid Rebates

Oct 08 2016

Related Companies

Viatris Inc.

Meridian Medical Technologies Inc.

Pfizer Inc.

Viatris Inc.

Agila Specialties Pvt. Ltd.

GSK plc

Sanofi

Kaléo Pharmaceutical Inc.

Merck KGaA

King Pharmaceuticals, Inc.

Additional Topics

United States Recalls Manufacturing Quality BioPharmaceutical Respiratory

More from Manufacturing

More from Compliance

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.